All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
The Lymphoma Hub is excited to present a visual abstract representing key data externally validating the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) model and comparing its model performance with the International Prognostic Index model. We have previously reported on the prognostic value of 18F-FDG–PET metabolic heterogeneity in DLBCL after first-line immunochemotherapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
The prognostic value of 18F-FDG-PET metabolic heterogeneity in DLBCL after first-line immunochemotherapy
Nicolas Aide and colleagues investigated the prognostic value of 18F-FDG-positron emission tomography (PET) in patients with DLBCL treated with...
SOHO 2019 | The future of cellular therapy in hematological malignancies
A series of talks were made at SOHO 2019 on current and future advances and potential of cellular therapies in hematological malignancies, focusing on CAR T, TAA T, NK and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox